Lupin receives US FDA approval for generic Topicort ointment

It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Lupin has received final approval for its Desoximetasone Ointment USP, 0.25 per cent from the United States Food & Drug Administration (FDA) to market a generic version of Taro Pharmaceuticals’ Topicort Ointment, 0.25 per cent.

Lupin’s Desoximetasone Ointment USP, 0.25 per cent is the AB rated generic equivalent of Taro Pharmaceuticals’ Topicort Ointment, 0.25 per cent. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topicort had US sales of $14.4 million (IMS MAT September 2016).

EP News Bureau